Since then, many MET‐activating mutations, located in the kinase domain, have been identified in nonhereditary papillary renal cancers [30] and found to induce constitutive MET activation, leading to cell transformation and tumor growth in experimental models. The gene discussed is MET; the disease is neoplasm.